Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution
NCT07105371 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2025-08-22
Summary
Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.
Conditions
- Motor Disorders
Interventions
- BIOLOGICAL
-
AlloEx exosomes
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
Sponsors & Collaborators
-
The Foundation for Orthopaedics and Regenerative Medicine
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-14
- Primary Completion
- 2025-03-14
- Completion
- 2025-03-14
Countries
- Antigua and Barbuda
Study Locations
More Related Trials
-
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT01142856 ·Status: COMPLETED ·Phase: PHASE1
-
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
NCT01730716 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
NCT00004771 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
NCT07118319 ·Status: RECRUITING ·Phase: PHASE1
-
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
NCT05306457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
NCT06649955 ·Status: RECRUITING ·Phase: NA
-
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
NCT05053035 ·Status: TERMINATED ·Phase: PHASE2
-
Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
NCT06598202 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Repeated Mesenchymal Stem Cell Injections in ALS
NCT04821479 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03537807 ·Status: NO_LONGER_AVAILABLE
-
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
NCT01605006 ·Status: COMPLETED ·Phase: NA
-
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
NCT02917681 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Effect and Safety MABs Administration m.3243A>G Mutation Carriers
NCT05962333 ·Status: RECRUITING ·Phase: PHASE2
-
Multiple Doses of AT-1501-A201 in Adults With ALS
NCT04322149 ·Status: COMPLETED ·Phase: PHASE2
-
Intermediate-size Patient Population Expanded Access Protocol
NCT07088159 ·Status: AVAILABLE
-
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01089010 ·Status: COMPLETED ·Phase: PHASE2
-
Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients
NCT02987413 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
NCT01051882 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
NCT03334786 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
NCT03828123 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
NCT02213705 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis
NCT02487407 ·Status: COMPLETED ·Phase: PHASE2
-
Early Feasibility Study of the MyoRegulator® for Treatment of ALS
NCT06165172 ·Status: COMPLETED ·Phase: NA